Furthermore, several studies have demonstrated that PAI-1 activity and the formation of tPA/PAI-1 complexes are substantially reduced in APL patients, likely as a result of proteolytic degradation of PAI-1, which prevents adequate control of disease-driven tPA hyperactivity [9]. This evidence concerns the gene SERPINE1 and acute promyelocytic leukemia.